Clinical Study
Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study
Table 3
Toxicity (24 patients).
| | Toxicity | Grade (CTCAE ver.3.0) | Grade 3/4 (%) | | 1 | 2 | 3 | 4 |
| | Hematologic | | | | | | | Leukopenia | 5 | 10 | 7 | 1 | 33 | | Neutropenia | 3 | 8 | 5 | 7 | 50 | | Anemia | 5 | 11 | 6 | 2 | 33 | | Thrombocytopenia | 9 | 4 | 1 | 0 | 4 | | Nonhematologic | | | | | | | Anorexia | 10 | 7 | 3 | 0 | 13 | | Nausea/vomiting | 5 | 1 | 0 | 0 | 0 | | Diarrhea | 11 | 3 | 1 | 0 | 4 | | Fatigue | 13 | 8 | 0 | 0 | 0 | | Febrile neutropenia | — | — | 3 | 0 | 13 | | Pneumonitis | 1 | 0 | 0 | 0 | 0 |
|
|
CTCAE: Common Terminology Criteria for Adverse Events.
|
